Maze Therapeutics initiates dosing in Phase I Pompe disease therapy trial
Maze has commenced participant dosing in its Phase I clinical trial of oral glycogen synthase (GYS1) inhibitor, MZE001, to treat Pompe diseas
Source: clinicaltrialsarena.com
Stay updated with breaking news from Cellular Immune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Maze has commenced participant dosing in its Phase I clinical trial of oral glycogen synthase (GYS1) inhibitor, MZE001, to treat Pompe diseas
Clinical research companies IACT Health, LMC Manna Research and True North Clinical Research have joined forces to form Centricity Research.
Sensorion announced that Phase II trial of SENS-401 (Arazasetron) to treat sudden sensorineural hearing loss failed to meet primary goal.
I-Mab has dosed the first subject in Phase II trial of efineptakin alfa plus pembrolizumab in advanced solid tumour patients in China.